US Broker Ratings

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Is a 100% Upside Within Reach?

GoodRx Holdings, Inc. (NASDAQ: GDRX) stands as a fascinating player in the healthcare sector, specializing in health information services within the United States. With a market capitalization of approximately $792.19..

Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena

Beam Therapeutics Inc. (NASDAQ: BEAM) stands as a compelling player in the biotechnology sector, with a market capitalization of $2.83 billion. Headquartered in Cambridge, Massachusetts, Beam is pioneering the field..

Organon & Co. (OGN) Stock Analysis: Evaluating Healthcare’s Undervalued Opportunity with a 14% Upside

Organon & Co. (NYSE: OGN), a notable player in the healthcare sector, is attracting attention from investors with its diverse portfolio of prescription therapies and medical devices. With a market..

Phreesia, Inc. (PHR): Investor Outlook with 116.74% Potential Upside

Phreesia, Inc. (PHR) is making waves in the healthcare sector with its innovative SaaS-based solutions, offering a robust platform for patient intake and payment services. Based in Wilmington, Delaware, Phreesia..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Exploring a 29% Potential Upside in the Medical Devices Sector

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a prominent player in the medical devices industry, is capturing investor attention with a notable potential upside of 29.18%. Headquartered in San Diego, California,..

LifeStance Health Group, Inc. (LFST): Analyst Consensus Points to 23.8% Upside Potential

Investors eyeing the healthcare sector might find LifeStance Health Group, Inc. (LFST) an intriguing option, given the company’s promising upside potential and its focus on expanding mental health services across..

Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector

Disc Medicine, Inc. (NASDAQ: IRON), a promising name in the biotechnology sector, is capturing investor attention with its substantial 51.37% potential upside. This clinical-stage biopharmaceutical company, with a market cap..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring a 57% Potential Upside for Investors

Investors with a keen eye on the biotechnology sector might find Centessa Pharmaceuticals plc (NASDAQ: CNTA) an intriguing proposition. With a substantial market capitalization of $3.72 billion, Centessa is a..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 20% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a key player in the healthcare sector specializing in medical instruments and supplies, is drawing investor attention with its promising growth prospects. Headquartered in Burlington,..

Premier, Inc. (PINC) Stock Analysis: Navigating a Flat Landscape with 2.97% Dividend Yield

Premier, Inc. (NASDAQ: PINC), a key player in the healthcare sector, operates primarily in the health information services industry. With a market cap of $2.34 billion, this Charlotte, North Carolina-based..

SS Innovations International (SSII) Stock Analysis: Exploring the 192.50% Revenue Growth in the Healthcare Sector

SS Innovations International, Inc. (SSII), a key player in the medical devices industry, is making waves with its substantial 192.50% revenue growth. Headquartered in Gurugram, India, this healthcare company is..

Galapagos NV (GLPG) Stock Analysis: A High-Stakes Bet in Biotechnology with an 18.9% Revenue Growth

Galapagos NV (GLPG), a Belgian biotechnology powerhouse, is an intriguing player in the healthcare sector. With a market capitalization of $2.26 billion, Galapagos continues to draw attention in the biotechnology..

ImmunityBio, Inc. (IBRX) Stock Analysis: Exploring a Potential 92.5% Upside

Investors with an eye on the biotechnology sector may find ImmunityBio, Inc. (NASDAQ: IBRX) an intriguing prospect. With its current market cap standing at $6.04 billion and a robust pipeline..

IDEAYA Biosciences (IDYA): Unpacking the 46.63% Potential Upside in Precision Oncology

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is gaining notable attention in the biotechnology sector, offering a promising proposition for investors keen on the precision oncology market. With its strategic focus on..

Certara, Inc. (CERT) Investor Outlook: Evaluating a 49% Potential Upside in Health Information Services

Certara, Inc. (NASDAQ: CERT) is drawing attention in the healthcare sector, particularly in the health information services industry, where it operates as a key player providing technology-enabled solutions for biosimulation...

PROCEPT BioRobotics (PRCT) Stock Analysis: A 74% Potential Upside in the Medical Robotics Field

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is making waves in the healthcare sector, specifically within the medical devices industry. The company’s focus on developing transformative solutions in urology has captured the..

Enovis Corporation (ENOV) Stock Analysis: A 103% Upside Potential in the Healthcare Sector

Enovis Corporation (ENOV), a prominent player in the healthcare sector specializing in medical devices, has caught the attention of investors with its compelling growth prospects and substantial upside potential. With..

Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is a noteworthy player in the biotechnology sector, focusing on the development and commercialization of treatments for rare diseases. With a market capitalization of $4.48..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Chinese Healthcare Sector

BGM Group Ltd. (BGM), a burgeoning player in the Chinese healthcare sector, offers an intriguing opportunity for investors with a penchant for high-risk, high-reward scenarios. Specializing in the manufacture and..

Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis: 23% Potential Upside in the Healthcare Sector

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is making waves in the healthcare sector with its promising portfolio of biopharmaceutical innovations targeted at cardiovascular and inflammatory diseases. With a market capitalization..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds